Jackson Authors Unanimous Supreme Court Ruling

Justice Ketanji Brown Jackson delivered a unanimous Supreme Court opinion Thursday in a closely watched pharmaceutical patent dispute, handing down a ruling that could carry major consequences for generic drug manufacturers, brand-name pharmaceutical companies, and American consumers.

The Court ruled 9-0 in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., reversing a lower court decision and sending the case back for additional proceedings.

The unanimous outcome was notable given Jackson’s frequent role as one of the Court’s more consistent dissenters. In this case, however, all nine justices joined her opinion.

The dispute centered on when patent-infringement claims against generic drug companies can move forward, particularly in cases involving so-called “skinny labels.” These FDA-approved labels allow generic manufacturers to omit patented uses of a medication while still selling the generic drug for non-patented purposes.

The Court’s decision provides important guidance for a highly technical but economically significant area of patent law. The ruling clarifies how courts should evaluate whether a generic drug manufacturer may be held liable when its product label excludes patented uses but its marketing or related materials allegedly encourage infringement.

The case carries major stakes for the pharmaceutical industry because generic drugs make up the overwhelming majority of prescriptions filled across the United States. Generic competition is also one of the main forces that helps reduce prescription drug prices for American families.

Industry groups and generic manufacturers warned that a ruling too favorable to Amarin could have opened the door to expanded litigation against generic companies. That, they argued, could discourage competition, delay market entry, and keep lower-cost alternatives out of reach for patients.

Newsweek reported that the lower courts had split on the issue before the Supreme Court stepped in.

“A federal district court dismissed the case, but the U.S. Court of Appeals for the Federal Circuit allowed it to proceed, finding the allegations plausible,” the outlet reported.

“The case is part of an ongoing effort by the court to clarify how patent law applies to generic drugs under the Hatch-Waxman Act, which governs competition between brand-name and generic pharmaceuticals,” it said.

The ruling also serves as a reminder that not every Supreme Court case follows the partisan storyline often pushed by the media. While high-profile constitutional disputes frequently produce ideological divides, many of the Court’s decisions are still resolved unanimously or through broad coalitions.

For Jackson, the decision also highlights her developing position on the Court.

According to statistics from the Court’s 2024-25 term, Jackson joined the majority in about 72 percent of decided cases, the lowest rate among the nine justices, Newsweek noted. Thursday’s ruling, however, showed that even on a divided Court, technical questions of law can still produce full agreement.

Beyond the pharmaceutical case, the Supreme Court has also agreed to revisit a major immigration dispute involving a long-running border policy known as “metering.”

The policy limited the number of asylum seekers who could enter at ports of entry along the southern border. President Donald Trump asked the justices to review a Ninth Circuit ruling that found the policy unlawful.

The Biden administration had abolished the practice, but the Trump administration is seeking to preserve executive flexibility as it strengthens immigration enforcement and border security policies.

Earlier this year, U.S. Solicitor General John Sauer argued that courts should not seize authority over border management from the political branches.

“The Constitution delegates the power to regulate the border to the political branches, not the judiciary,” Sauer asserted.

Sauer said the Ninth Circuit’s ruling interfered with Congress’s role in shaping asylum policy and undermined the executive branch’s constitutional authority to manage the nation’s borders.

“Based on the reasoning of the decision below, [Customs and Border Patrol] was barred from impeding the entry of an individual who presented themselves at the border without a prior appointment,” Sauer asserted.

“An alien may claim to have arrived ‘in the United States,’ thereby requiring governmental inspection and processing of his asylum application, which would allow him to bypass the queue,” Sauer added.

“The asylum-seekers challenged the government’s petition, claiming that the appellate court’s ruling applied exclusively to a particular cohort of migrants,” Sauer continued.

The dispute centers on how federal asylum law applies to migrants who reach the border and claim a right to seek asylum. Under the Immigration and Nationality Act, individuals who are physically present in the United States may apply for asylum if they can establish a well-founded fear of persecution in their home country.

For conservatives, the case presents another critical test of whether the judiciary will respect the constitutional authority of the elected branches to secure the border.

President Trump’s argument is straightforward: border policy should be made by the political branches accountable to the American people, not by lower courts stretching immigration law to limit executive enforcement power.

Together, the Court’s actions Thursday show the range of issues now before the justices, from highly technical pharmaceutical patent questions to major constitutional disputes over sovereignty, immigration enforcement, and the separation of powers.